tiprankstipranks
Advertisement
Advertisement

AARD Stock Latest News

Ram Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds
RatingsRam Selvaraju Maintains Hold on Aardvark, Assigns $6 Valuation Amid FDA Clinical Hold on ARD-101 and Lowered Approval Odds
13d ago
AARD
Aardvark Therapeutics Implements Executive Retention Bonus Agreements
PremiumCompany Announcements
Aardvark Therapeutics Implements Executive Retention Bonus Agreements
2M ago
8K
AARD
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4
PremiumRatings
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4
3M ago
AARD
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
PremiumThe Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
3M ago
AARD
NBIX
Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley
PremiumThe Fly
Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley
3M ago
AARD
Aardvark Therapeutics Inc trading halted, volatility trading pause
PremiumThe FlyAardvark Therapeutics Inc trading halted, volatility trading pause
3M ago
AARD
Aardvark Therapeutics Inc trading resumes
Premium
The Fly
Aardvark Therapeutics Inc trading resumes
3M ago
AARD
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
Premium
The Fly
Aardvark Therapeutics downgraded to Neutral from Buy at BTIG
3M ago
AARD
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
3M ago
AARD
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program
PremiumCompany Announcements
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program
3M ago
8K
AARD
Aardvark Therapeutics announces FDA clinical hold on ARD-101
PremiumThe Fly
Aardvark Therapeutics announces FDA clinical hold on ARD-101
3M ago
AARD
Aardvark Therapeutics price target lowered to $18 from $20 at BofA
PremiumThe Fly
Aardvark Therapeutics price target lowered to $18 from $20 at BofA
3M ago
AARD
Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
PremiumThe FlyAardvark Therapeutics reports Q1 EPS (99c), consensus (91c)
3M ago
AARD
Options Volatility and Implied Earnings Moves Today, April 06, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves Today, April 06, 2026
4M ago
AARD
AIRS
Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
Premium
Market News
Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
4M ago
BB
BLK
AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
AARD
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
PremiumThe Fly
Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
4M ago
AARD
Aardvark Therapeutics Establishes $150 Million Equity Program
PremiumCompany Announcements
Aardvark Therapeutics Establishes $150 Million Equity Program
4M ago
8K
AARD
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
PremiumRatings
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks
4M ago
AARD
Closing Bell Movers: Core Labs falls after below-consensus pre-announcement
PremiumThe FlyClosing Bell Movers: Core Labs falls after below-consensus pre-announcement
4M ago
APO
CLB
Aardvark Therapeutics files $400M mixed securities shelf
Premium
The Fly
Aardvark Therapeutics files $400M mixed securities shelf
4M ago
AARD
Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
Premium
The Fly
Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
4M ago
AARD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >